Alogliptin (NESINA), a dipeptidyl peptidase IV (DPP-4) inhibitor, was approved by the FDA on January 25, 2013 to improve blood sugar control in adults with type 2 diabetes. This drug had been ...

Another reason for the postponement of the alogliptin PDUFA date could be related to the FDA's recent announcement that manufacturers developing new drugs and biologics for type 2 diabetes will ...

platform technology and internally discovered drug candidates, including the dipeptidyl peptidase 4 inhibitor alogliptin, which has been submitted for regulatory approval to treat diabetes.

If you are already taking both alogliptin and metformin as separate tablets, Nesina Met can replace them in one tablet. Nesina Met is not for patients with type 1 diabetes mellitus or diabetic ...